Sibylle Loibl, MD, on Clinical Challenges Associated With Use of Palbociclib and Endocrine Therapy for HR+ HER2– Breast Cancer

Posted: Tuesday, December 22, 2020

Sibylle Loibl, MD, of the German Breast Group, discusses phase III findings from the PENELOPE-B trial and the questions her research group intends to explore to improve overall adjuvant treatment for patients with hormone receptor–positive, HER2-negative breast cancer who are at high risk for relapse.